- Home
- BON vs ADTX Comparison
BON vs ADTX Comparison
Compare BON & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- ADTX
- Stock Information
- Founded
- BON 2006
- ADTX 2017
- Country
- BON China
- ADTX United States
- Employees
- BON N/A
- ADTX N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- ADTX Health Care
- Exchange
- BON Nasdaq
- ADTX Nasdaq
- Market Cap
- BON 6.1M
- ADTX 5.3M
- IPO Year
- BON 2021
- ADTX 2020
- Fundamental
- Price
- BON $1.49
- ADTX $0.19
- Analyst Decision
- BON
- ADTX
- Analyst Count
- BON 0
- ADTX 0
- Target Price
- BON N/A
- ADTX N/A
- AVG Volume (30 Days)
- BON 35.8K
- ADTX 1.9M
- Earning Date
- BON 02-07-2025
- ADTX 11-18-2024
- Dividend Yield
- BON N/A
- ADTX N/A
- EPS Growth
- BON N/A
- ADTX N/A
- EPS
- BON 2.22
- ADTX N/A
- Revenue
- BON $25,555,939.00
- ADTX $212,107.00
- Revenue This Year
- BON $47.04
- ADTX $95.61
- Revenue Next Year
- BON $77.63
- ADTX $1,584.79
- P/E Ratio
- BON $0.66
- ADTX N/A
- Revenue Growth
- BON N/A
- ADTX N/A
- 52 Week Low
- BON $1.23
- ADTX $0.19
- 52 Week High
- BON $6.00
- ADTX $338.80
- Technical
- Relative Strength Index (RSI)
- BON 45.41
- ADTX 16.52
- Support Level
- BON $1.37
- ADTX $0.19
- Resistance Level
- BON $1.75
- ADTX $0.39
- Average True Range (ATR)
- BON 0.16
- ADTX 0.03
- MACD
- BON -0.02
- ADTX 0.09
- Stochastic Oscillator
- BON 21.00
- ADTX 1.10
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from perfumes and fragrance products.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.